Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853083 | 0.80 | ALDH1A1 (0.60) | ALDH1A1EGLN3CYP19A1ALPIALPG | |
| SCHEMBL10856981 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TBXAS1CYP19A1BRD4 | |
| SCHEMBL15883223 | 0.79 | EGLN3 (0.47) | ALDH1A1TBXAS1EGLN3 | |
| SCHEMBL563845 | 0.77 | ALDH1A1 (0.56) | ALDH1A1TBXAS1EGLN3CYP19A1 | |
| SCHEMBL6262180 | 0.77 | ALDH1A1 (0.56) | ALDH1A1EGLN3CYP19A1ALPIALPG | |
| SCHEMBL4968495 | 0.77 | ALDH1A1 (0.60) | ALDH1A1TBXAS1EGLN3CYP19A1ALPI | |
| SCHEMBL4837064 | 0.76 | DTYMK (0.47) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27678497 | 0.76 | ALDH1A1 (0.55) | ALDH1A1TBXAS1EGLN3CYP19A1ALPG | |
| SCHEMBL28928213 | 0.76 | ALDH1A1 (0.41) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6893393 | 0.75 | TBXAS1 (0.53) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314701-B2 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2008-01-01 | — | — | US | claimed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2023-11-23 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11712481-B2 | Lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-08-01 | — | — | US | disclosed |
| US-11712481-B2 | Lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-08-01 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2008157050-A1 | PROCESSES FOR MANUFACTURING BISPHOSPHONIC ACIDS | ALBEMARLE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1996599-A2 | PROCESS FOR MANUFACTURING BISPHOSPHONIC ACIDS | Albermarle Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7314701-B2 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2008-01-01 | — | — | US | disclosed |
| WO-2007109542-A2 | PROCESS FOR MANUFACTURING BISPHOSPHONIC ACIDS | ALBEMARLE CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109542-A2 | PROCESS FOR MANUFACTURING BISPHOSPHONIC ACIDS | ALBEMARLE CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20050095527-A1 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-0773926-A1 | DIFLUOROSTATONE ANTIVIRAL AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002499-A1 | DIFLUOROSTATONE ANTIVIRAL AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| US-4584008-A | FUNGICIDES AND PLANT GROWTH REGULATORS | CHEVRON RESEARCH COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0102163-A1 | Triazole derivatives and compositions containing the same | CHEVRON RESEARCH COMPANY (US) | 1984-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712481-B2 | Lipid nanoparticle formulations | LIPA, PLIN3, PLIN1 | ALDH1A1 1911/4885TBXAS1 1317/4885EGLN3 225/4885 |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | LIPA, PLIN3, PLIN1 | ALDH1A1 1911/4885TBXAS1 1317/4885EGLN3 225/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885TBXAS1 2858/4885EGLN3 2566/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885TBXAS1 2858/4885EGLN3 2566/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | ALDH1A1 4532/4885TBXAS1 2889/4885EGLN3 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.